franckreporter/iStock via Getty Images
- Aclaris Therapeutics (ACRS) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa.
- Esperion Therapeutics (ESPR) -27% amid Nexletol data showing reduced risk of heart events.
- Adaptimmune Therapeutics (ADAP) -23% after strategic combination with TCR² Therapeutics; tops Q4 consensus.
- Embark Technology (EMBK) -16%.
- Etao International (ETAO) -12%.
- Cardio Diagnostics (CDIO) -11%.
- Asset Entities (ASST) -10%.
- OncoSec Medical (ONCS) -10%.
- Performance Shipping (PSHG) -7%.
- Silvergate Capital (SI) -7% after Silvergate Capital cut to Underperform at Wedbush on potential for liquidation.
- Blackboxstocks (BLBX) -7%.
- Altamira Therapeutics (CYTO) -6%.
- BioMarin Pharmaceutical (BMRN) -6%.
- Bullfrog AI (BFRG) -5%.